<DOC>
	<DOCNO>NCT01590797</DOCNO>
	<brief_summary>A study compare safety efficacy sitagliptin placebo therapy add stable insulin alone combination metformin participant type 2 diabetes mellitus ( T2DM ) . The primary hypothesis study 24 week , addition sitagliptin compare placebo provide great reduction hemoglobin A1C ( HbA1C ) T2DM participant insulin alone combination metformin .</brief_summary>
	<brief_title>A Study China Evaluating Safety Efficacy Adding Sitagliptin Stable Therapy With Insulin With Without Metformin Participants With Type 2 Diabetes Mellitus ( T2DM ) ( MK-0431-254 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>T2DM currently stable regimen premixed , intermediateacting , longacting insulin dose least 12 U/day , either alone combination metformin &gt; =1500 mg/day ≥ 10 week Visit 1/Screening HbA1C 7.5 % 11.0 % male , female highly unlikely conceive study 14 day last dose study medication treat antihyperglycemic therapy protocolrequired insulin ( alone metformin ) within prior 12 week ever treat dipeptidyl peptidase4 inhibitor glucagonlike peptide1 mimetic analogue currently treatment daily use ( one injection per day ) preprandial shortacting rapidacting insulin history 2 episode hypoglycemia result seizure , coma , loss consciousness , recurrent episode hypoglycemia past 8 week history intolerance hypersensitivity , contraindication sitagliptin , insulin , metformin weight loss program maintenance phase , start weight loss medication undergone bariatric surgery within 12 month undergone surgical procedure within 4 week plan major surgery study medical history active liver disease new worsen sign symptom coronary heart disease within past 3 month , acute coronary syndrome , coronary artery intervention , stroke transient ischemic neurological disorder diagnosis congestive heart failure New York Heart Association Class III IV cardiac status systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 90 mmHg human immunodeficiency virus ( HIV ) severe peripheral vascular disease currently treat hyperthyroidism thyroid hormone therapy stable dose least 6 week history malignancy ≤ 5 year study , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) pregnant breast feeding , expect conceive donate egg study , include 14 day last dose study medication user recreational illicit drug recent history drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>